HER2-POSITIVE GASTRIC CANCER
Clinical trials for HER2-POSITIVE GASTRIC CANCER explained in plain language.
Never miss a new study
Get alerted when new HER2-POSITIVE GASTRIC CANCER trials appear
Sign up with your email to follow new studies for HER2-POSITIVE GASTRIC CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for tough stomach cancers: testing a Triple-Threat treatment
Disease control Recruiting nowThis study is testing a new three-drug combination for people with advanced stomach or gastroesophageal cancer that has a specific marker called HER2-positive. The main goals are to find the safest and most effective dose of the new drug fruquintinib when added to two standard ca…
Matched conditions: HER2-POSITIVE GASTRIC CANCER
Phase: PHASE1, PHASE2 • Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
Major trial launches for advanced stomach cancer: new drug combo challenges standard treatment
Disease control Recruiting nowThis large Phase 3 trial is testing whether a new combination of cancer drugs works better than current standard treatment for advanced HER2-positive stomach cancer. The study will enroll 840 patients with previously untreated, advanced stomach or gastroesophageal junction cancer…
Matched conditions: HER2-POSITIVE GASTRIC CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 25, 2026 14:09 UTC
-
Breakthrough trial aims to extend lives in aggressive stomach cancers
Disease control Recruiting nowThis large Phase 3 study is testing whether adding a new antibody drug called HLX22 to standard treatment helps people with advanced HER2-positive stomach or gastroesophageal cancer live longer without their cancer getting worse. About 550 adults with previously untreated, advanc…
Matched conditions: HER2-POSITIVE GASTRIC CANCER
Phase: PHASE3 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated Mar 17, 2026 13:08 UTC